How long does it take to lose 2 stone on Mounjaro?

What does the trial data actually suggest about losing 2 stone?

The SURMOUNT-1 trial followed adults with obesity over 72 weeks and found average weight reductions of around 20–21% at the 15 mg dose. For someone starting at 14 stone (89 kg), 2 stone is roughly a 14% reduction, a threshold many participants crossed before the halfway point of the trial. At lower doses, the same 14% was reached later, and some participants did not reach it at all.

That last point matters. Clinical trials report averages across thousands of participants. Within any group, some people lose weight faster, some more slowly, and a proportion lose less than expected at a given dose. Framing 2 stone as a guaranteed milestone by a fixed date is the biggest misconception worth letting go of gently: it sets people up for unnecessary disappointment when their body is simply responding on its own timeline.

What the evidence does show clearly is a consistent dose-response pattern. Higher doses produce greater average losses. The titration schedule (starting at 2.5 mg and stepping up roughly every four weeks) means the first pen is about helping your body adjust, not about dramatic early numbers. Results tend to accelerate once maintenance doses are reached, which for many people means months 3 to 6 are where meaningful movement happens. You can read more about how long Mounjaro takes to start working in the earlier weeks.

Which factors most affect how quickly 2 stone comes off?

Starting weight is significant. Someone at 18 stone has a larger absolute amount to shift before reaching 2 stone off; in percentage terms the target is smaller (around 11%), so they may reach it faster. Someone starting at 13 stone needs to lose a higher proportion of their weight to hit the same milestone, and may find it takes longer.

Dose is probably the most controllable variable. Reaching 10 mg or 15 mg safely is associated with substantially greater average losses than staying at 5 mg, though not everyone tolerates higher doses at the same pace. Diet and activity play a role too, tirzepatide is licensed alongside a reduced-calorie diet and increased physical activity, not as a stand-alone fix. Patients who make meaningful lifestyle changes alongside treatment consistently do better in the data.

Other factors (sleep quality, stress, underlying metabolic conditions, and whether type 2 diabetes is present) all affect pace. People with type 2 diabetes tend to lose weight a little more slowly on average in the trial data, though they still achieve clinically meaningful losses. For a sense of what different weight targets look like on a longer timeline, the 3 stone and 4 stone pages cover what the evidence suggests at those levels.

Is 2 stone in the first few months realistic?

For some people, yes. For others, no. The honest answer depends on where you start and what dose you reach. The fastest losses in the SURMOUNT-1 data came from participants who reached 15 mg and had higher starting BMIs. If you begin at a BMI of 40 and tolerate dose increases well, losing 2 stone in 16–20 weeks is within the range the trial data supports. If you start at a lower BMI, tolerate titration more slowly, or plateau at an intermediate dose, 24–36 weeks is more typical.

A note on the first few weeks: many people report modest losses in weeks 1 to 4, sometimes less than a pound. Some of that is normal fluid shift; some is the titration period doing its job. Reading too much into week-by-week fluctuations is rarely helpful. The early-week experience page covers what people commonly notice at the start of treatment.

For context on what reaching larger targets looks like over a longer treatment course, the pages on losing 5 stone and losing 6 stone draw on the same SURMOUNT evidence. Cost is a practical consideration for a private treatment, the Mounjaro pricing page gives an honest picture of what private treatment involves.

What should you do if 2 stone feels far off after several months?

First, check whether your dose has been optimised. Many people who feel they have plateaued are still on an intermediate dose and have not yet reached the level where the trial data shows the strongest effect. A prescriber review is the right step, not stopping treatment unilaterally.

Second, look honestly at the lifestyle side. Tirzepatide reduces appetite significantly, but if overall calorie intake has crept back up, or activity has stayed very low, that will blunt results. The NHS guidance on weight management recommends combining medication with dietary and activity support throughout treatment.

Third, some people genuinely respond less to this class of medicine than others. If meaningful weight loss has not occurred after six months at the highest tolerated dose, your prescriber will review whether continuing makes sense, this is standard clinical practice, not a failure. The Mounjaro overview page covers the full picture of how treatment works and who it suits. If you want to explore your eligibility or discuss your situation with a prescriber, you can check your eligibility with our clinical team.